(secondQuint)Gefitinib in Treating Patients With Recurrent or Metastatic Esophageal or Gastroesophageal Junction Cancer.

 OBJECTIVES: Primary - Explore the activity of single agent gefitinib, in terms of response rate, in a patient population with recurrent or metastatic esophageal or gastroesophageal junction cancer.

 Secondary - Assess the toxicity of this drug in these patients.

 OUTLINE: Patients are stratified according to prior treatment (yes vs no).

 Patients receive oral gefitinib once daily for at least 8 weeks in the absence of disease progression or unacceptable toxicity.

 After completion of study treatment, patients are followed periodically for survival.

 PROJECTED ACCRUAL: A total of 76 patients will be accrued for this study.

.

 Gefitinib in Treating Patients With Recurrent or Metastatic Esophageal or Gastroesophageal Junction Cancer@highlight

RATIONALE: Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

 PURPOSE: This phase II trial is studying how well gefitinib works in treating patients with recurrent or metastatic esophageal or gastroesophageal junction cancer.

